Stefano Ferrara

APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant <i>nab</i>-paclitaxel plus gemcitabine (<i>nab</i>-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

Margaret A. Tempero, Michele Reni, Hanno Riess et al. · Journal of Clinical Oncology · 2019 · 143 citations

Surgical Oncology, Cancer Management, Pharmacotherapy +17

Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly <i>nab-</i>Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

Josep Tabernero, E. Gabriela Chiorean, Jeffrey R. Infante et al. · The Oncologist · 2015 · 140 citations · Full text

Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly et al. · Journal of Clinical Oncology · 2022 · 120 citations · Full text

Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)

David Goldstein, Daniel D. Von Hoff, Malcolm J. Moore et al. · European Journal of Cancer · 2015 · 50 citations · Full text

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer

Lucas Moreno, Michela Casanova, Julia Chisholm et al. · European Journal of Cancer · 2018 · 32 citations · Full text

Phase I/ii Study, Medicine, Metronomic Therapy +7